Navigation Links
Ireland Cancer Center researcher finds standard treatment for breast cancer not followed
Date:12/21/2007

Research out of the Ireland Cancer Center of University Hospitals Case Medical Center, in collaboration with six integrated health plans that are part of the Cancer Research Network, found that the majority of older women with early stage breast cancer fail to adhere to the standard of treatment five years of daily oral use of the chemo-prevention drug Tamoxifen. To be published in the February issue of Journal of Clinical Oncology and released earlier this month, Cynthia Owusu, MD, of the Ireland Cancer Center (ICC) and colleagues determined that premature tamoxifen discontinuation is quite common and deserves closer attention.

We in the medical community have long believed we were caring for these women appropriately and this study determines that these patients over age 65 are being woefully undertreated, said Dr. Owusu, who runs the ICCs geriatric oncology program and was lead author of the study. Going forward we need to develop strategies to improve breast cancer outcomes for these women.

The study looked at 961 women over the age of 65 who had early stage hormone positive breast cancer. Previous research has shown that five years of Tamoxifen is more effective than two years of use. However, information on tamoxifen discontinuation has been scanty. Dr. Owusu and her group sought to identify factors that predict premature tamoxifen continuation.

They found that nearly 50% of the women in the study discontinued tamoxifen before the completion of five years. The women most likely to stop taking the treatment were women over age 75, women who developed other medical illnesses during the first three years of follow-up and those who had their breast lumps removed but failed to receive radiation after their surgery. The discontinuation of Tamoxifen may result in earlier recurrences, and ultimately, increased breast cancer mortality.

This study is the first to show that closer attention to non-adherence among older women at risk of premature discontinuation might improve breast cancer survival for these women, explains Dr. Owusu. These findings have major clinical implications for this large group of breast cancer survivors. It means we have to really examine what to do to counteract this discontinuation, such as working more closely with primary care providers and increasing patient education. We really have to pay close attention to older patients more likely to fall into this category.

These results remind us to educate our patients about the value of prompt diagnosis and complete treatment. Only through closer follow-up care for older women with breast cancer, will we achieve optimal results and allow these women to lead healthy lives, said Stanton Gerson, MD, Director of the Ireland Cancer Center.


'/>"/>

Contact: Alicia Reale
Alicia.Reale@UHhospitals.org
216-844-5158
University Hospitals of Cleveland
Source:Eurekalert

Related medicine news :

1. University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisas Legacy Fund for Cancer Research and Education
2. Carrington Subsidiary DelSite to Present at International Vaccine Conference in Ireland
3. PulseLearning (Founded in Childs Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland
4. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
5. Survival differences by race most apparent in advanced stages of breast cancer
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. Pathway links inflammation, angiogenesis and breast cancer
9. Radiologists encouraged to look beyond cancer for clinically unseen diseases
10. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
11. Immune deficiency linked to a type of eye cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: